WallStSmart

Lineage, Inc. Common Stock (LINE)vsSeritage Growth Properties (SRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 25851% more annual revenue ($5.36B vs $20.64M). SRG leads profitability with a 0.0% profit margin vs -1.9%. SRG earns a higher WallStSmart Score of 36/100 (F).

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: 0.81

SRG

Hold

36

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LINEUndervalued (+75.9%)

Margin of Safety

+75.9%

Fair Value

$161.49

Current Price

$35.99

$125.50 discount

UndervaluedFair: $161.49Overvalued
SRGUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$3.40

Current Price

$2.55

$0.85 discount

UndervaluedFair: $3.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

SRG2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
231.1%10/10

Revenue surging 231.1% year-over-year

Areas to Watch

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

SRG4 concerns · Avg: 2.5/10
Market CapQuality
$143.63M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-18.5%2/10

ROE of -18.5% — below average capital efficiency

EPS GrowthGrowth
-97.6%2/10

Earnings declined 97.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : SRG

The strongest argument for SRG centers on Price/Book, Revenue Growth. Revenue growth of 231.1% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Bear Case : SRG

The primary concerns for SRG are Market Cap, Profit Margin, Return on Equity.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while SRG is a hypergrowth play — different risk/reward profiles.

SRG is growing revenue faster at 231.1% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LINE scores higher overall (36/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.

Visit Website →

Seritage Growth Properties

REAL ESTATE · REAL ESTATE SERVICES · USA

Seritage Growth Properties is a publicly traded, self-managed and self-managed REIT with 166 wholly owned properties and 29 unconsolidated properties totaling approximately 30.

Want to dig deeper into these stocks?